Business Wire

CT-TII

Share
Technology Innovation Institute’s Cryptography Research Centre in Abu Dhabi Collaborates with Yale University

Abu Dhabi and the UAE are working to pioneer breakthroughs in post-quantum cryptography and neuromorphic computing through an international partnership between Technology Innovation Institute’s (TII) Cryptography Research Centre (CRC) and Yale University, an Ivy League research university in Connecticut, United States.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210106005376/en/

The two institutions will first join forces on ‘Post-Quantum Lightweight Crypto Hardware Accelerators and Trusted Execution Environment Designs’, a project at the intersection of emerging technologies that focuses on developing quantum-resistant crypto schemes within the context of emerging quantum algorithms that can be run on a sufficiently large quantum computer. By leveraging post-quantum cryptographic (PQC) algorithms, the project aims to guarantee the necessary measures of security even as today’s public cryptographic standards, such as RSA and Elliptic Curve Cryptography (ECC), become ineffective when a powerful quantum computer is built and can run Shor’s quantum algorithm. The project is also exploring post-quantum lightweight cryptography with a focus on highly constrained devices.

The neuromorphic computing project, ‘Energy-based Probing for Robust and Explainable Spiking Neural Networks’, takes inspiration from the brain to create energy-efficient hardware for information processing and is capable of highly sophisticated tasks. The project examines Spiking Neural Networks (SNNs), which have become popular as an energy-efficient alternative for implementing standard artificial intelligence tasks. Spikes or binary events drive communication and computation in SNNs that are close to biological neuronal processing and offer the benefit of event-driven hardware operations.

The central focus of the collaboration is to explore the design space of the energy-accuracy-robustness-explainability trade-off and to design the hardware/software necessary to create truly functional intelligent systems. To ensure there is no overlap, both entities have been tasked with managing specific areas of the research in both projects.

Speaking on the partnership, Dr Najwa Aaraj, Chief Researcher at Cryptography Research Centre, said: “We are excited to work with peers from Yale University in carrying out groundbreaking research in these two vital fields. At the Cryptography Research Centre, we are creating a knowledge-driven ecosystem powered by like-minded scientists and researchers – all focused on designing breakthrough solutions in different areas of cryptography.”

Jakub Szefer, Associate Professor of Electrical Engineering and Computer Science, and Priya Panda, Assistant Professor of Electrical Engineering, from Yale University, said: “By working collaboratively with Cryptography Research Centre, we have an opportunity to apply shared expertise across post-quantum cryptography and neuromorphic computing research. We are optimistic that this partnership will yield effective research outcomes for greater impact.”

Technology Innovation Institute, the ‘applied research’ pillar of Advanced Technology Research Council (ATRC), is a pioneering global research and development centre that focuses on applied research and new-age technology capabilities. The institute has seven initial dedicated research centres in quantum, autonomous robotics, cryptography, advanced materials, digital security, directed energy and secure systems. By working with exceptional talent, universities, research institutions and industry partners from all over the world, the Institute connects an intellectual community and contributes to building an R&D ecosystem in Abu Dhabi and the UAE. The Institute reinforces Abu Dhabi and the UAE’s status as a global hub for innovation and contributes to the broader development of the knowledge- based economy.

For more information about Cryptography Research Centre (CRC) please visit

tii.ae/cryptographytii.ae/cryptography

*Source: AETOSWire

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release

First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi

Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 08:42:00 CET | Press release

Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable

GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 08:30:00 CET | Press release

Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus

Hisense Joins HEVC Advance Patent Pool22.12.2025 03:06:00 CET | Press release

Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye